Transrail Lighting Soars 11% After Strong Q4 Print, Order Wins Boost FY25 Outlook

26 May 2025
1 min read
Transrail Lighting Soars 11% After Strong Q4 Print, Order Wins Boost FY25 Outlook
whatsapp
facebook
twitter
linkedin
telegram
copyToClipboard

Shares of Transrail Lighting surged as much as 10.7% to ₹632.80 on Monday, marking the stock's sharpest intraday gain since January 16. As of 10:37 AM, the stock was trading 5.5% higher at ₹603 apiece, significantly outperforming the Nifty50, which rose 0.72% in early trade. This marks the stock’s fifth consecutive session of gains, with a rally of over 35% from its recent low of ₹451 recorded earlier this month.

The jump follows the company’s robust earnings for the March quarter (Q4FY25), where consolidated net profit rose 27% YoY to ₹327 crore. Revenue from operations surged 40% YoY to ₹1,946.02 crore, backed by continued strength in the engineering and project services vertical.

For the full year, net profit climbed 40% to ₹327 crore from ₹233 crore in FY24, while annual revenue rose 30% to ₹5,307.75 crore. The company attributed the performance to disciplined execution, operational efficiencies, and strength across key verticals.

Order inflow remained a standout metric. In Q4 alone, Transrail secured new orders worth ₹4,965 crore, bringing the full-year intake to ₹9,680 crore - a majority coming from the transmission and distribution (T&D) sector. The company closed the year with an unexecuted order book of ₹14,551 crore, up 44% YoY.

“We closed FY25 with excellent performance across all operational parameters - marked by strong revenue growth, benchmark margins, and record order inflows,” said Randeep Narang, MD & CEO.

Transrail Lighting, with a current market cap of ₹8,158.74 crore, operates as a leading EPC player in the power infrastructure space, offering end-to-end solutions in T&D, civil construction, railways, solar EPC, and pole and lighting systems.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here

Do you like this edition?